Table 3 Adverse effects reported in the studies.
Drug class | Study | Intervention | Adverse effects (MRA) | Adverse effects (comparator) |
|---|---|---|---|---|
MRA versus diuretics | Douglas 1974 | Sp 400 mg compared to Hct 100+Tr 200 mg | Breast tenderness 11.7% Amenorrhoea 5.9% Impotence 11.7% Muscle cramps 17.6% Lassitude 23.5% Hypokalaemia 0% Angina and hypotension 0% | Breast tenderness 0% Amenorrhoea 0% Impotence 0% Muscle cramps 23.5% Lassitude 23.5% Hypokalaemia 5.9% Angina and hypotension 5.9% |
Spark 1974 | Sp 400 mg compared to Hct 200 mg | None | Hypokalaemia and muscle cramps (% NR) | |
Kreeft 1983 | Sp 400 mg compared to Ch 100 mg | Orthostatic dizziness 16% | Orthostatic dizziness 0% | |
MRA versus ACEi/ARB | Weinberger 2005 | E100–200mg compared to Lo 50–100 mg | Gynaecomastia 2.3% Irregular menses 0% Impotence 1.2% Hyperkalaemia: 1.2% | Gynaecomastia 0% Irregular menses 2.4% Impotence 1.2% Hyperkalaemia: 0% |
MRA versus ENaCi | DeCarvalho 1980 | Sp 100-mg compared to Tr 100-mg | Orthostatic dizziness and hypotension 8% | Orthostatic dizziness and hypotension 0% |
MRA versus placebo | Carey 1972 | Sp 400 mg compared to placebo | Breast tenderness 0% Impotence 12.5% Muscle cramps 8.3% General weakness 4.2% | Breast tenderness 0% Impotence 0% Muscle cramps 0% General weakness 0% |
Saruta 2004 | Ep 50,100,200 mg compared to placebo | Breakdown NR. No difference between groups. | ||
